https://doi.org/10.4081/monaldi.2022.2324

Clinico-epidemiological profile of COVID-19 patients admitted during third wave of pandemic in a tertiary care hospital in New Delhi, India

Vol. 93 No. 2 (2023)
Submitted: May 12, 2022
Accepted: August 11, 2022
Published: September 5, 2022
COVID-`19, third wave, Omicron, vaccination
Abstract Views: 804
PDF: 261
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Shreyash Agrawal
Department of Pulmonary, Critical Care and Sleep Medicine, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India.
Ravindra Nath
Department of Preventive and Social Medicine, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India.
Pranav Ish
Department of Pulmonary, Critical Care and Sleep Medicine, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India.
Neeraj Kumar Gupta
Department of Pulmonary, Critical Care and Sleep Medicine, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India.
Rajni Gaind
Department of Microbiology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India.
Suniti Kale
Department of Anesthesia and Intensive Care, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India.
Rani Gera
Department of Pediatrics, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India.
Anjali Dabral
Department of Obstetrics and Gynecology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India.
Nitesh Gupta
niteshgupta2107@gmail.com
https://orcid.org/0000-0002-5842-5584
Department of Pulmonary, Critical Care and Sleep Medicine, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India.
*Other members of the Safdarjung Hospital COVID 2019 working group
Safdarjung Hospital, New Delhi, India.

Even nearly two years after the first reported case, the novel coronavirus (SARS-CoV-2) continues to ebb and flow around the world. A retrospective cohort study was carried out to determine the clinico-epidemiological profile and outcome of the cases. The study analyzed secondary data from 827 patients who presented to our center with COVID-19-related illnesses between December 15, 2021, and February 15, 2022 (third wave in India). There was a significant difference in the vaccination status of patients treated at home and those admitted, with 87.9% having received two doses compared to 74% in the second group being unvaccinated. Patients who were isolated at home recovered at a rate of 99.4%, while hospitalized patients died at a rate of 26.5%. Vaccination reduces the severity of COVID-19; however, constant vigilance for new variants, precautionary measures, and increased vaccination drives are critical moving forward.

 

*Other members of the Safdarjung Hospital COVID-19 working group: B. Lal (Medicine), Harish Sachdeva (Anaesthesiology), Santvana Kohli (Anaesthesiology), Amandeep Jaswal (Anaesthesiology), Sumitra Bachani (Obstetrics and Gynecology), Ajay Kumar (Pediatrics), Rohit Kumar (Pulmonary Medicine), Vidya Sagar Chaturvedi (Surgery), Vinod Chaitanya (Medicine).

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
Nature.com [Internet]. Where did Omicron come from? Three key theories. Accessed March 25, 2021.Available from: https://www.nature.com/articles/d41586-022-00215-2
Li L, Huang T, Wang Y, et al. COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol 2020;92:577-83. DOI: https://doi.org/10.1002/jmv.25757
Picon RV, Carreno I, da Silva AA, et al. Coronavirus disease 2019 population-based prevalence, risk factors, hospitalization, and fatality rates in southern Brazil. Int J Infect Dis 2020;100:402-40. DOI: https://doi.org/10.1016/j.ijid.2020.09.028
Government of Delhi, Department of Information & Publicity. Delhi fights Corona. Bulletin. Accessed March 25, 2021. Available from: https://delhifightscorona.in/news/
Government of NCT of Delhi. Guide to home isolation. Accessed March 25, 2021. Available from: https://delhifightscorona.in/wp-content/uploads/2020/06/DG_Home-Isolation-Guidelines-Eng.pdf
Indian Council of Medical Research. Advisory on purposive testing strategy for COVID-19 in India (Version VII, dated January 10, 2022). Accessed March 25, 2021. Available from: https://www.icmr.gov.in/pdf/covid/strategy/Advisory_COVID_Testing_10012022.pdf
World Health Organization. Statement on Omicron sublineage B.A.2. Accessed March 25, 2021. Available from: https://www.who.int/news/item/22-02-2022-statement-on-omicron-sublineage-ba.2
Maslo C, Friedland R, Toubkin M, et al. Characteristics and outcomes of hospitalized patients in South Africa during the COVID-19 Omicron wave compared with previous waves. JAMA 2022;327:58384. DOI: https://doi.org/10.1001/jama.2021.24868
Abdullah F, Myers J, Basu D, et al. Decreased severity of disease during the first global omicron variant covid-19 outbreak in a large hospital in Tshwane, South Africa. Int J Infect Dis 2022;116:38-42. DOI: https://doi.org/10.1016/j.ijid.2021.12.357
Iuliano AD, Brunkard JM, Boehmer TK, et al. Trends in disease severity and health care utilization during the early Omicron variant period compared with previous SARS-CoV-2 high transmission periods - United States, December 2020-January 2022. MMWR Morb Mortal Wkly Rep 2022;71:146-152. DOI: https://doi.org/10.15585/mmwr.mm7104e4
Das S, Kar SS, Samanta S, et al. Immunogenic and reactogenic efficacy of Covaxin and Covishield: a comparative review. Immunol Res 2022;70:289-315. DOI: https://doi.org/10.1007/s12026-022-09265-0
Parikh PM, Maheshwari U, Krishna VM, et al. Robust protective effect of COVID-19 vaccination in India-Results of Survey in the midst of pandemic's second wave. South Asian J Cancer 2021;10:28-31. DOI: https://doi.org/10.1055/s-0041-1733320
Bharat Biotech [Internet]. COVAXIN® (BBV152) Booster shown to neutralize both Omicron and Delta variants of SARS-CoV-2. Accessed March 25, 2021. Available from: https://www.bharatbiotech.com/images/press/covaxin-neutralize-delta-and-omicron-variants-press-release.pdf
Buchan SA, Chung H, Brown KA, et al. Effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and severe outcomes. medRxiv 2021.12.30.21268565. DOI: https://doi.org/10.1101/2021.12.30.21268565

Ethics approval

Institutional Ethical Committee approval obtained for the study (IEC/VMMC/SJH/Project/2021-03/CC-136)

How to Cite

Agrawal, Shreyash, Ravindra Nath, Pranav Ish, Neeraj Kumar Gupta, Rajni Gaind, Suniti Kale, Rani Gera, Anjali Dabral, Nitesh Gupta, and *Other members of the Safdarjung Hospital COVID 2019 working group. 2022. “Clinico-Epidemiological Profile of COVID-19 Patients Admitted During Third Wave of Pandemic in a Tertiary Care Hospital in New Delhi, India”. Monaldi Archives for Chest Disease 93 (2). https://doi.org/10.4081/monaldi.2022.2324.
Copyright (c) 2022 The Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.